Everest Medicines Ltd (1952.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG3224E1061
Everest Medicines Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 706.00 m CNY | 1.71 bn CNY |
| Gross profit | 528.00 m CNY | 1.18 bn CNY |
| EBIT | -1.12 bn CNY | -386.15 m CNY |
| Net income | -1.04 bn CNY | -297.77 m CNY |
| Diluted EPS – continuing operations | -3.21 CNY | -0.86 CNY |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Everest Medicines Ltd
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.
More stocks
- Mezzion Pharma Co.Ltd (140410.KQ)
- Guangdong Anda Automation Solutions Co. Ltd. A (688125.SS)
- Taiwan Hon Chuan Enterprise Co Ltd (9939.TW)
- Vivenio Residencial SOCIMI SA (YVIV.MC)
- Creades publ AB (CRED A.ST)
- ITMAX System Berhad (5309.KL)
- Motorcomm Electronic Technology Co. Ltd. A (688515.SS)
- Dongwon Ind (006040.KS)
- Zhejiang Guyuelongshan Shaoxing Wine Co Ltd (600059.SS)
- VERDE BIO HOLDINGS, INC. (APHD)
- AcadeMedia AB (ACAD.ST)
- Shenzhen Sunline Tech Co Ltd (300348.SZ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.